Eric A Epping1, Ji-In Kim1, David Craufurd1, Thomas M Brashers-Krug1, Karen E Anderson1, Elizabeth McCusker1, Jolene Luther1, Jeffrey D Long1, Jane S Paulsen1. 1. From the Departments of Psychiatry and Neurology, Carver College of Medicine, University of Iowa, Iowa City; the Department of Biostatistics, College of Public Health, University of Iowa, Iowa City; the Department of Psychology, University of Iowa, Iowa City; the Institute of Human Development, University of Manchester, Manchester, U.K.; the Huntington Disease Care, Education, and Research Center and the Departments of Psychiatry and Neurology, MedStar Georgetown University Hospital, Washington, D.C.; and the Department of Neurology, Westmead Hospital, University of Sydney, Sydney, Australia.
Abstract
OBJECTIVE: Psychiatric symptoms are a significant aspect of Huntington's disease, an inherited neurodegenerative illness. The presentation of these symptoms is highly variable, and their course does not fully correlate with motor or cognitive disease progression. The authors sought to better understand the development and longitudinal course of psychiatric manifestations in individuals who carry the Huntington's disease mutation, starting from the prodromal period prior to motor diagnosis. METHOD: Longitudinal measures for up to 10 years of psychiatric symptoms from the Symptom Checklist-90-Revised were obtained from 1,305 participants (1,007 carrying the Huntington's disease mutation and 298 without [classified as controls]) and 1,235 companions enrolled in the Neurobiological Predictors of Huntington's Disease (PREDICT-HD) study. Participants with the mutation were stratified into three groups according to probability of motor diagnosis within 5 years. Using linear mixed-effects regression models, differences in psychiatric symptoms at baseline and over time between the mutation-positive groups and the controls were compared, as well as between ratings by mutation-positive participants and their companions. RESULTS: Nineteen of 24 psychiatric measures (12 participant ratings and 12 companion ratings) were significantly higher at baseline and showed significant increases longitudinally in the individuals with the Huntington's disease mutation compared with controls. The differences were greatest in comparisons of symptom reports from companions compared with self-reports, especially in participants who were closest to motor diagnosis. CONCLUSIONS: The results indicate that psychiatric manifestations develop more often than previously thought in the Huntington's disease prodrome. Symptoms also increase with progression of disease severity. Greater symptom ratings by companions than by mutation-positive participants suggest decreasing awareness in those affected.
OBJECTIVE:Psychiatric symptoms are a significant aspect of Huntington's disease, an inherited neurodegenerative illness. The presentation of these symptoms is highly variable, and their course does not fully correlate with motor or cognitive disease progression. The authors sought to better understand the development and longitudinal course of psychiatric manifestations in individuals who carry the Huntington's disease mutation, starting from the prodromal period prior to motor diagnosis. METHOD: Longitudinal measures for up to 10 years of psychiatric symptoms from the Symptom Checklist-90-Revised were obtained from 1,305 participants (1,007 carrying the Huntington's disease mutation and 298 without [classified as controls]) and 1,235 companions enrolled in the Neurobiological Predictors of Huntington's Disease (PREDICT-HD) study. Participants with the mutation were stratified into three groups according to probability of motor diagnosis within 5 years. Using linear mixed-effects regression models, differences in psychiatric symptoms at baseline and over time between the mutation-positive groups and the controls were compared, as well as between ratings by mutation-positive participants and their companions. RESULTS: Nineteen of 24 psychiatric measures (12 participant ratings and 12 companion ratings) were significantly higher at baseline and showed significant increases longitudinally in the individuals with the Huntington's disease mutation compared with controls. The differences were greatest in comparisons of symptom reports from companions compared with self-reports, especially in participants who were closest to motor diagnosis. CONCLUSIONS: The results indicate that psychiatric manifestations develop more often than previously thought in the Huntington's disease prodrome. Symptoms also increase with progression of disease severity. Greater symptom ratings by companions than by mutation-positive participants suggest decreasing awareness in those affected.
Authors: K Duff; J Paulsen; J Mills; L J Beglinger; D J Moser; M M Smith; D Langbehn; J Stout; S Queller; D L Harrington Journal: Neurology Date: 2010-07-07 Impact factor: 9.910
Authors: Eric A Epping; James A Mills; Leigh J Beglinger; Jess G Fiedorowicz; David Craufurd; Megan M Smith; Mark Groves; Kelly R Bijanki; Nancy Downing; Janet K Williams; Jeffrey D Long; Jane S Paulsen Journal: J Psychiatr Res Date: 2013-06-19 Impact factor: 4.791
Authors: Elizabeth A McCusker; David G Gunn; Eric A Epping; Clement T Loy; Kylie Radford; Jane Griffith; James A Mills; Jeffrey D Long; Jane S Paulsen Journal: Neurology Date: 2013-08-21 Impact factor: 9.910
Authors: Sarah J Tabrizi; Rachael I Scahill; Gail Owen; Alexandra Durr; Blair R Leavitt; Raymund A Roos; Beth Borowsky; Bernhard Landwehrmeyer; Chris Frost; Hans Johnson; David Craufurd; Ralf Reilmann; Julie C Stout; Douglas R Langbehn Journal: Lancet Neurol Date: 2013-05-09 Impact factor: 44.182
Authors: Noelle E Carlozzi; Siera Goodnight; Anna L Kratz; Julie C Stout; Michael K McCormack; Jane S Paulsen; Nicholas R Boileau; David Cella; Rebecca E Ready Journal: J Huntingtons Dis Date: 2019
Authors: Dan P Covey; Hannah M Dantrassy; Samantha E Yohn; Alberto Castro; P Jeffrey Conn; Yolanda Mateo; Joseph F Cheer Journal: Neuropsychopharmacology Date: 2018-06-01 Impact factor: 7.853
Authors: Katherine L Possin; Hosung Kim; Michael D Geschwind; Tacie Moskowitz; Erica T Johnson; Sharon J Sha; Alexandra Apple; Duan Xu; Bruce L Miller; Steven Finkbeiner; Christopher P Hess; Joel H Kramer Journal: Neuropsychologia Date: 2017-04-17 Impact factor: 3.139
Authors: Natalie E Zlebnik; Iness Gildish; Thibaut Sesia; Aurelie Fitoussi; Ellen A Cole; Brian P Carson; Roger Cachope; Joseph F Cheer Journal: Cereb Cortex Date: 2019-12-17 Impact factor: 5.357
Authors: Shawn Minnig; Robert M Bragg; Hardeep S Tiwana; Wes T Solem; William S Hovander; Eva-Mari S Vik; Madeline Hamilton; Samuel R W Legg; Dominic D Shuttleworth; Sydney R Coffey; Jeffrey P Cantle; Jeffrey B Carroll Journal: Sci Rep Date: 2018-02-02 Impact factor: 4.379
Authors: Xiaoying Tang; Christopher A Ross; Hans Johnson; Jane S Paulsen; Laurent Younes; Roger L Albin; J Tilak Ratnanather; Michael I Miller Journal: Hum Brain Mapp Date: 2018-10-30 Impact factor: 5.038
Authors: Flor A Espinoza; Jingyu Liu; Jennifer Ciarochi; Jessica A Turner; Victor M Vergara; Arvind Caprihan; Maria Misiura; Hans J Johnson; Jeffrey D Long; Jeremy H Bockholt; Jane S Paulsen; Vince D Calhoun Journal: Hum Brain Mapp Date: 2019-01-07 Impact factor: 5.038
Authors: Andrew McGarry; Michael P McDermott; Karl Kieburtz; Wai Lun Alan Fung; Elizabeth McCusker; Jing Peng; Elisabeth A de Blieck; Merit Cudkowicz Journal: Neurology Date: 2019-03-08 Impact factor: 9.910